Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,076 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BBT-877, Single dose, Placebo group, BBT-877, Multiple doses
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Jonathan B. Zuckerman
Other
Eligibility
6 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Conditions
Cystic Fibrosis, Burkholderia Infections
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151 (Zinpentraxin Alfa)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
40
States / cities
Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more
Completed Phase 1 Interventional Results available

Phase 1 Study to Assess Safety and Efficacy of ANG003

NCT06052293
Conditions
Exocrine Pancreatic Insufficiency
Interventions
ANG003
Drug
Lead sponsor
Anagram Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more
Completed No phase listed Observational Accepts healthy volunteers

Immunological Characterization of Bronchoalveolar Cells in Normals

NCT00843414
Conditions
Lung Disease
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
1,232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1978 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Scleroderma, Systemic
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
Conditions
Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg
Drug
Lead sponsor
Hal Chapman
Other
Eligibility
40 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
Conditions
Cystic Fibrosis (CF), Cystic Fibrosis Gastrointestinal Disease
Interventions
Mediterranean diet
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
3 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Lebanon, New Hampshire • Manchester, New Hampshire
Conditions
Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression
Interventions
Palliative Care, Standard of Care
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Cystic Fibrosis
Interventions
Nitric Oxide for Inhalation, Nitrogen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
Interventions
Nintedanib, Placebo Oral Tablet
Drug
Lead sponsor
Temple University
Other
Eligibility
35 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
COVID-19
Interventions
APX-115, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more
Conditions
Cystic Fibrosis
Interventions
LUM/IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
Completed Phase 1 Interventional Accepts healthy volunteers

Airway Alkalinization and Nasal Colonization

NCT03078088
Conditions
Healthy Subjects, Cystic Fibrosis
Interventions
Tham, Saline
Drug
Lead sponsor
Lakshmi Durairaj
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Not listed Not applicable Interventional Accepts healthy volunteers

Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury

NCT01910818
Conditions
Chronic Radiation Dermatitis
Interventions
Fractional CO2 laser treatment, No treatment
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cystic Fibrosis, Quality of Life
Interventions
Implementation of Primary Palliative Care Intervention in CF Centers
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Detecting Lung Infections Through Vibration

NCT02056860
Conditions
Lung Infection
Interventions
Group 1 will receive 15 Hz, Group 2 will receive 30 Hz, Group 3 will receive 60 Hz, Group 4 will receive 100 Hz, Phase II Optimal Frequency
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Completed Not applicable Interventional Results available

Early Intervention in Cystic Fibrosis Exacerbation

NCT01104402
Conditions
Cystic Fibrosis
Interventions
Home lung function and symptom monitoring
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Baltimore, Maryland • Seattle, Washington
Conditions
Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Cystic Fibrosis
Interventions
Essential amino acid intake + Leucine vs total AA supplement
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
10 Years to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Milene Saavedra
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Denver, Colorado